Table 3.
Time to event comparison of the reduced and full doses for each individual DOAC (Dabigatran, Rivaroxaban, and Apixaban).
| Events | D75 (n = 53) |
D150 (n = 57) |
Univariable p value (log rank test) | Multivariable hazard ratio (95 % CI) * |
R15 (n = 224) |
R20 (n = 74) |
Univariable p value (log rank test) | Multivariable hazard ratio (95 % CI) * |
A2.5 (n = 236) |
A5 (n = 68) |
Univariable p value (log rank test) | Multivariable hazard ratio (95 % CI) * |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| %/year | %/year | %/year | %/year | %/year | %/year | |||||||
| SSE | 1.1 | 0 | N/A | N/A | 1.1 | 0 | N/A | N/A | 0.8 | 0 | N/A | N/A |
| CNS bleed | 2.2 | 0.5 | N/A | N/A | 1.7 | 0.6 | 0.32 | N/A | 0.8 | 0 | N/A | N/A |
| Non-CNS bleed | 12.1 | 1.6 | < 0.001 | 0.343 (CI: 0.07 to 1.62) |
12.4 | 7.2 | 0.18 | 1.16 (CI: 0.53 to 2.5) |
8.3 | 3.7 | 0.18 | 1.091 (CI: 0.28 to 4.2) |
| All-cause mortality | 5.5 | 3.8 | 0.41 | N/A | 4.2 | 0 | < 0.001 | N/A | 9.5 | 0.9 | 0.005 | 0.083 (CI: 0.01 to 0.7) |
SSE = Stroke and systemic embolization; CNS = Central nervous system; D150: Dabigatran 150 mg twice daily; D75: Dabigatran 75 mg twice daily; R20: Rivaroxaban 20 mg daily; R15: Rivaroxaban 15 mg daily; A5: Apixaban 5 mg twice daily; A2.5: Apixaban 2.5 mg twice daily. *p values and CI adjusted for multivariable baseline differences using proportional hazards. The reduced group was the reference group. Some results were not available (N/A) either because the univariable analysis was not significant or because there were too few patients in one or both outcome groups for a meaningful analysis.